SAN.PA Earnings Date: Oct 30, 2026 (Estimated) — Sanofi

PAR

Updated Oct 30, 2026

Price —

Market Cap $91.4B

P/E 22.9

52W Range — – —

Next Earnings Oct 30, 2026 (est.)

When is SAN.PA's next earnings date?

Sanofi (SAN.PA) is expected to report earnings on Friday, October 30, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.80 on revenue of $12.81B.

How did SAN.PA do in its last earnings report?

In its most recent report on Jul 30, 2026, Sanofi posted EPS of $2.09 versus the $1.90 estimate, a beat. Revenue was $12.30B against a $13.30B estimate.

How much does SAN.PA stock move after earnings?

SAN.PA beat EPS estimates in 1 of its last 1 reported quarter.

About Sanofi

Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.

🤖 AI Earnings Analysis

SAN.PA trades at 22.9× earnings with a 16.7% profit margin; without recent news or earnings comparisons, valuation alone suggests limited insight into near-term performance.

AI-generated summary — powered by BigEarnings.